Reduced mammographic density with use of a gonadotropin-releasing hormone agonist - Based chemoprevention regimen in BRCA1 carriers

Clinical Cancer Research

Volumn 13, Issue 2 I, 2007, Pages 654-658

  Weitzel, Jeffrey N ^a,b   Buys, Saundra S ^c   Sherman, William H ^d   Daniels, AnnaMarie ^e   Ursin, Giske ^b,f   Daniels, John R ^b,e   MacDonald, Deborah J ^a   Blazer, Kathleen R ^a   Pike, Malcolm C ^b,e   Spicer, Darcy V ^b,e  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e Prosthetic/Orthotic Specialists   (United States)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DESLORELIN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; TESTOSTERONE;

ADULT; ARTICLE; BONE DENSITY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERANCE; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; HOT FLUSH; HUMAN; MAMMOGRAPHY; MENSTRUATION; METERED DOSE INHALER; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTICARCINOGENIC AGENTS; BONE DENSITY; ESTRADIOL; FEMALE; GENES, BRCA1; GONADOTROPIN-RELEASING HORMONE; HETEROZYGOTE; HUMANS; MAMMOGRAPHY; MEDROXYPROGESTERONE 17-ACETATE; MUTATION; QUALITY OF LIFE; STEROIDS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33846874825     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1902     Document Type: Article

References (31)

1. Kauft ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
2. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
3. Weitzel JN. Genetic testing for breast cancer predisposition. In: Jatoi I, editor. Breast cancer screening. Medical Intelligence Unit. Austin: RG Landes Co.; 1997. p 155-78.
4. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-62.
5. Daly MB, Axilbund JE, Bryant E, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2006;4:156-76.
6. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005;23:1644-55.
7. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993;259:633-8.
8. Pike MC, Ross RK, Lobo RA, et al. LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 1989;60:142-8.
9. Spicer DV, Shoupe D, Pike MC. GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception 1991;44:289-309.
10. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.
11. Spicer DV, Pike MC, Pike A, et al. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 1993;47:427-44.
12. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
13. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94.
14. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-9.
15. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126:1130-7.
16. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003;12:332-8.
17. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
18. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
19. Duffy SW, Jakes RW, Ng FC, Gao F. Interaction of dense breast patterns with other breast cancer risk factors in a case-control study. Br J Cancer 2004;91:233-6.
20. Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:2833-8.
21. Ursin G, Palla SL, Reboussin BA, et al. Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Clin Oncol 2004;22:2842-8.
22. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-8.
23. Ursin G, Astrahan MA, Salane M, et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998;7:43-7.
24. Ganz PA, Day R, Ware JE, Jr., Redmond C, Fisher B. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 1995;87:1372-82.
25. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
26. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center Hospital; 1993.
27. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev 2001;10:141-2.
28. Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 2001;10:1117-20.
29. Rebbeck TR, Friebel T, Wagner T, et al. Effect of Short-term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. J Clin Oncol 2005;23:7804-10.
30. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. J Natl Cancer Inst 2002;94:1773-9.
31. Ursin G, Henderson BE, Haile RW, et al. Does oral Contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997;57:3678-81.